CASI Net Tangible Assets from 2010 to 2026
| CASI Stock | USD 0.92 0.03 3.16% |
Net Tangible Assets | First Reported 2011-06-30 | Previous Quarter 51.7 M | Current Value 31.7 M | Quarterly Volatility 42.7 M |
Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 795.3 K, Selling General Administrative of 28.5 M or Other Operating Expenses of 82.3 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0092 or PTB Ratio of 28.32. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.
CASI | Net Tangible Assets | Build AI portfolio with CASI Stock |
The Net Tangible Assets trend for CASI Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether CASI Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest CASI Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of CASI Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. CASI Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CASI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
CASI Net Tangible Assets Regression Statistics
| Arithmetic Mean | 47,451,596 | |
| Geometric Mean | 29,212,338 | |
| Coefficient Of Variation | 75.15 | |
| Mean Deviation | 31,415,176 | |
| Median | 50,296,045 | |
| Standard Deviation | 35,658,842 | |
| Sample Variance | 1271.6T | |
| Range | 115.5M | |
| R-Value | 0.72 | |
| Mean Square Error | 657.9T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 5,067,215 | |
| Total Sum of Squares | 20344.8T |
CASI Net Tangible Assets History
About CASI Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as CASI Pharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 83.1 M | 50.3 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of CASI Pharmaceuticals Correlation against competitors. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.